VEA
VERV

Virtus ETF Advisers’s Verve Therapeutics VERV Stock Holding History

Virtus ETF Advisers’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,411
Closed -$64.4K – 789
2024
Q4 		$64.4K Sell
11,411
-5,044
-31% -$28.4K 0.03% 424
2024
Q3 		$79.6K Buy
16,455
+290
+2% +$1.68K 0.04% 414
2024
Q2 		$78.9K Buy
16,165
+10,119
+167% +$63.6K 0.04% 408
2024
Q1 		$80.3K Sell
6,046
-419
-6% -$5.56K 0.04% 393
2023
Q4 		$90.1K Buy
6,465
+683
+12% +$8.47K 0.06% 403
2023
Q3 		$76.7K Sell
5,782
-577
-9% -$9.29K 0.05% 368
2023
Q2 		$119K Buy
6,359
+1,888
+42% +$31.4K 0.07% 329
2023
Q1 		$64.5K Sell
4,471
-1,724
-28% -$33.8K 0.04% 415
2022
Q4 		$120K Buy
+6,195
New +$164K 0.06% 418

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Virtus ETF Advisers's VERV Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Verve Therapeutics (VERV) in Q1 2025, closing a stake of 11,411 shares — an estimated $64.4K sold.

Virtus ETF Advisers first reported a position in VERV in Q4 2022 and held it in 9 quarters. The position peaked at $120K in Q4 2022. 191 funds tracked by Wall St. Rank hold VERV as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Verve Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 11,411 Verve Therapeutics shares in Q1 2025, an estimated $64.4K.
  • Virtus ETF Advisers first reported a position in Verve Therapeutics in Q4 2022 and held it in 9 quarters.
  • Virtus ETF Advisers's Verve Therapeutics position peaked at $120K in Q4 2022.
  • 191 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.